NEW YORK – Direct-to-consumer custom probiotics and gut health company Sun Genomics said on Monday that it has closed an $8.7 million Series A funding round.
The round was led by Pangaea Ventures, with additional investments from Danone Manifesto Ventures, SOSV, Human Longevity, and Nascita Ventures. Pangaea Ventures Founding General Partner Chris Erickson has also joined Sun Genomics' board of directors.
The firm was founded in 2016 when it released its flagship product Floré, a microbiome test that uses whole-genome sequencing to evaluate the microbial content of a customer's digestive system combined with a personalized gut probiotic based on that customer's unique gut profile. The company also offers Floré Tots, which is available for kids up to age 12. Since Sun Genomics' seed funding in October 2019, the company has raised $11.8 million in total.
The company said it will use this new round of funding to support its growth in the custom probiotics market, scale delivery of its products across the US, enter international markets, and publish new studies in partnership with academic institutions.
"As we continue to understand the connection between the microbes in our gut and immune system dysfunction, consumers are becoming increasingly interested in their own personal microbiome, seeking solutions to gut-related issues," Sun Genomics Founder and CEO Sunny Jain said in a statement. "We are building the world's largest longitudinal dataset to better understand gut health, allowing us to custom design probiotics for the exact needs of each and every customer."